The Global Antibacterials Market: R&D Pipelines, Market Analysis and Competitive Landscape

Table of Contents

1 EXECUTIVE SUMMARY

2 INTRODUCTION TO BACTERIAL DISEASES

• 2.1 Group A Streptococcus (GAS)
• 2.2 Group B Streptococcus (GBS)
• 2.3 Streptococcus pneumoniae
• 2.4 Haemophilus Influenzae
• 2.5 Neisseria Meningitidis
• 2.6 Methicillin Resistant Staphylococcus Aurens (MRSA)

3 PATIENT DEMOGRAPHICS

• 3.1 Group A Streptococcus (GAS) Patient Statistics
• 3.2 Group B Streptococcus (GBS) Patient Statistics
• 3.3 Streptococcus pneumoniae Patient Statistics
• 3.4 Haemophilus Influenzae Patient Statistics
• 3.5 Neisseria Meningitidis Patient Statistics
• 3.6 MRSA Patient Statistics

4 KEY DRIVERS

• 4.1 Drug Resistance
• 4.2 New Treatments
• 4.3 Patient Demographics
• 4.4 Vaccines
• 4.5 Potential for Clinical Success
• 4.6 Indirect Cost Associated with Infectious Diseases

5 KEY RESISTORS

• 5.1 Over-prescription
• 5.2 Antibiotic Resistance Leading to Short Antibacterial Drug Lifecycles
• 5.3 Acute Use of Antibiotics
• 5.4 Generics
• 5.5 Curative Therapies and Vaccines

6 THE MARKET

• 6.1 The Global Anti-infective Market
• 6.2 Market Segments
• 6.3 Global Antibacterial Market
  • 6.3.1 Cephalosporin Antibiotics
  • 6.3.2 Macrolide Antibiotics
  • 6.3.3 Penicillin Antibiotics
  • 6.3.4 Quinolone Antibiotics
  • 6.3.5 Other Antibiotics
• 6.4 The Major Players
  • 6.4.1 Antibacterial Major Players in 2006
  • 6.4.2 Antibacterial Major Players in 2012
• 6.5 Market Trends
  • 6.5.1 Antibacterial Agents by 2012

7 LEADING ANTIBACTERIAL DRUG CLASSES

• 7.1 Aminoglycosides
• 7.2 Carbapenems
• 7.3 Cephalosporins
• 7.4 Glycopeptide
• 7.5 Ketolide
• 7.6 Lipopeptide
• 7.7 Macrolides
• 7.8 Penicillins
• 7.9 Oxazolidinones
• 7.10 Pleuromutilins
• 7.11 Quinolone

8 LEADING BRANDS

• 8.1 Aminogylcoside Antibiotics
  • 8.1.1 Tygacil (Wyeth)
  • 8.1.2 Leading Aminoglycoside Sales Forecasts
• 8.2 Carbapenem Antibiotics
  • 8.2.1 Finibax (Shionogi/ Johnson & Johnson/[Peninsula])
  • 8.2.2 Merrem/Meronem (AstraZeneca/Sumitomo Pharmaceuticals)
  • 8.2.3 Primaxin/Tieman (Merck & Co.)
  • 8.2.4 Leading Carbapenem Sales Forecasts
• 8.3 Cephalosporins
  • 8.3.1 Ceftin/Zinnat (GlaxoSmithKline)
  • 8.3.2 Flumarin (Shionogi)
  • 8.3.3 Omnicef/Cefzon (Abbott Laboratories/Astellas)
  • 8.3.4 Rocephin (Roche)
  • 8.3.5 Leading Cephalosporin Sales Forecasts
• 8.4 Glycopeptide Antibiotics
  • 8.4.1 Vancomycin (Shionogi/ViroPharm/[Eli Lilly])
  • 8.4.2 Targocid (Sanofi-Aventis/Astellas)
  • 8.4.3 Leading Glycopeptide Sales Forecasts
• 8.5 Ketolide Antibiotics
  • 8.5.1 Ketek (Sanofi-Aventis/Astellas)
  • 8.5.2 Leading Ketolide Sales Forecasts
• 8.6 Lipopeptide Antibiotics
  • 8.6.1 Cubicin (Cubist Pharmaceuticals/Novartis)
  • 8.6.2 Leading Lipopeptide Sales Forecasts
• 8.7 Macrolide Antibiotics
  • 8.7.1 Biaxin/Biaxin XL (Abbott Laboratories)
  • 8.7.2 Zithromax/Zmax (Pfizer)
  • 8.7.3 Macrolide Sales Forecasts
• 8.8 Oxazolidinone Antibiotics
  • 8.8.1 Zyvox/Zyvoxid (Pfizer)
  • 8.8.2 Leading Oxazolidinone Sales Forecasts
• 8.9 Penicillin Antibiotics
  • 8.9.1 Augmentin (GlaxoSmithKline)
  • 8.9.2 Zosyn/Tazocin (Wyeth)
  • 8.9.3 Leading Penicillin Sales Forecasts
• 8.10 Quinolone Antibiotics
  • 8.10.1 Avelox/Avalox (Astellas/Bayer/Schering-Plough)
  • 8.10.2 Levaquin/Cravit and Floxin/Tarivid (Johnson & Johnson/Daiichi Sankyo/Santen Pharmaceuticals)
  • 8.10.3 Cipro/Ciprobay/Ciproxin (Bayer/Schering-Plough)
  • 8.10.4 Leading Quinolone Sales Forecasts
• 8.11 Pleuromutilin Antibiotics
  • 8.11.1 Altabax/Altargo (GlaxoSmithKline)
  • 8.11.2 Leading Pleuromutilin Sales Forecasts
• 8.12 Other Antibiotics
• 8.13 Global Antibacterial Sales Forecasts

9 FUTURE BRANDS

• 9.1 Carbapenem Antibiotics
  • 9.1.1 Faropenem Medoxomil (Replidyne)
  • 9.1.2 PF-3,709,270 (Pfizer)
  • 9.1.3 R1558 (Roche/Daiichi-Sankyo)
• 9.2 Cephalosporin Antibiotics
  • 9.2.1 Ceftobiprole (J&J/[Basilea])
  • 9.2.2 Ceftaroline (Cerexa/[Takeda])
• 9.3 Dihydrofolate Reductase Inhibitor Antibiotics
  • 9.3.1 Iclaprim (Arpida/[Roche])
  • 9.3.2 AR-709 (Arpida)
• 9.4 Glycopeptide Antibiotics
  • 9.4.1 Oritavancin (Targanta/[InterMune])
  • 9.4.2 Telavancin (Astellas/Theravance)
  • 9.4.3 Zeven (Pfizer/[Vicuron Pharmaceuticals])
• 9.5 Ketolide Antibiotics
  • 9.5.1 Cethromycin (Advanced Life Sciences/[Abbott])
• 9.6 Macrolides
  • 9.6.1 S-013420 (Shionogi/[Enanta Pharmaceuticals])
  • 9.6.2 Quinolone
  • 9.6.3 ABT-492 (Abbott/[Wakunga Pharmaceuticals])
  • 9.6.4 DX-619 (Daiichi-Sankyo)
  • 9.6.5 Gracevit (Daiichi-Sankyo)
  • 9.6.6 Garenoxacin (Schering-Plough/[Toyama])
  • 9.6.7 Olamufloxacin (Abbott)
• 9.7 Other Antibiotics
  • 9.7.1 Aurograb (Novartis/[NeuTec])
  • 9.7.2 Tifacogin (Novartis/[Chiron])
  • 9.7.3 REP8839 (Replidyne)
• 9.8 Future Global Antibacterial Sales Forecasts

10 KEY COMPANY PROFILES

• 10.1 Advanced Life Sciences
• 10.2 Arpida Ltd
• 10.3 Basilea Pharmaceutica AG
• 10.4 Cerexa Inc.
• 10.5 Cubist Pharmaceuticals, Inc.
• 10.6 Targanta Therapeutics Corp.
• 10.7 Theravance

APPENDIX 3: Acronyms

TABLES

• Table 2.1 Infectious Disease Leading Worldwide Health Burden
• Table 4.1 Potential for Clinical Success
• Table 6.1 Historical Sales of Leading Antibiotics 2001-2005
• Table 7.1 Different Classes of Antibacterial Agents
• Table 8.1 Common Bacterial Infections
• Table 8.2 Sales Forecasts of Leading Aminoglycosides US$mn 2005A - 2012E
• Table 8.3 Sales Forecasts of Leading Carbapenems US$2005-2012E
• Table 8.4 Approved Cephalosporin Antibiotics
• Table 8.5 Sales Forecasts of Cephalosporins US$mn 2005-2012E
• Table 8.6 Sales Forecasts of Leading Glycopeptides US$mn 2005A - 2012E
• Table 8.7 Sales Forecasts of Ketolide Antibiotics US$mn 2005 - 2012E
• Table 8.8 Clinical Efficacy of Cubicin Versus Comparator on Pathogens
• Table 8.9 Sales Forecasts of Leading Lipopeptides US$mn 2005A - 2012E
• Table 8.10 Sales Forecasts of Leading Macrolides US$m 2005A - 2012E
• Table 8.11 Sales Forecasts of Leading Oxazolidinones US$m 2005A - 2012E
• Table 8.12 Approved Penicillins
• Table 8.13 Sales Forecasts of Leading Penicillins US$m 2005A - 2012E
• Table 8.14 Approved Quinolone Antibiotics
• Table 8.15 Sales Forecasts of Leading Quinolones US$m 2005A - 2012E
• Table 8.16 Sales Forecasts of Leading Pleuromutilins US$m 2005A - 2012E
• Table 8.17 Sales Summary of Leading Antibacterial Agents (US$m) 2005 - 2012E
• Table 9.1 Antibiotics in Clinical Development
• Table 9.2 DX-619 Potent Quinolone in Vitro Against Gram Positive Pathogens
• Table 9.3: Sales Summary of New Antibacterial Agents (US$m) 2005 - 2012E

FIGURES

• Figure 3.1 MRSA Among ICU Patients in the US, 1995-2004
• Figure 6.1 Global Anti-Infective Market 2006
• Figure 6.2 Global Anti-Infective Market 2015
• Figure 6.3 Antibacterial Sales Split - Drug Class Split 2006
• Figure 6.4 Cephalosporin Antibiotics - Leading Drugs 2006
• Figure 6.5 Macrolide Antibiotics - Leading Drugs 2006
• Figure 6.6 Penicillin Antibiotics - Leading Drugs 2006
• Figure 6.7 Quinolone Antibiotics - Leading Drugs 2006
• Figure 6.8 Other Antibiotics - Leading Drugs 2006
• Figure 6.9 The Major Players 2006
• Figure 6.10 The Major Players 2012
• Figure 6.11 Antibacterial Agents - Drug Class Split 2012
• Figure 7.1 Site of Action of Leading Antibacterial Agents
• Figure 9.1 Number of Drugs in Development to Treat Infectious Diseases
• Figure 9.2 Schematic of Drug-resistant Pathogens and Market Opportunities
• Figure 9.3 DX-619 Effective in Severe Infection Models Potent Quinolone in Vitro Against Gram Positive Pathogens
• Figure 9.4 DC-159a Effective in Severe RTI